Format

Send to

Choose Destination
Hum Mutat. 2019 Jun;40(6):832-833. doi: 10.1002/humu.23749. Epub 2019 Apr 18.

Response to: Concern regarding classification of germlineTP53 variants as likely pathogenic.

Author information

1
Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
2
Division of Research, National Cancer Institute, Mexico City, Mexico.
3
Department of Prevention and Therapy of Chronic Diseases, Team Tumor Molecular Pathology and Biomarkers, Institute for Advanced Biosciences, Inserm U 1209, UMR 5309 Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.
4
Department of Oncogenetics, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
5
Head and Neck Surgery and Otorhinolaryngology Department, A.C. Camargo Cancer Center, São Paulo, Brazil.
6
Oncogenetics Unit, Oncology Center, Sírio-Libanês Hospital, São Paulo, Brazil.

KEYWORDS:

Li-Fraumeni syndrome; TP53; gnomAD; prevalence; variant classification

PMID:
30997946
DOI:
10.1002/humu.23749
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center